본문 바로가기
  • Home

In vitro anthelmintic evaluation of common Indian Ayurvedic anthelmintic drugs: Krimimudgar Ras, Kriminol and Vidangasava against intestinal helminths

  • CELLMED
  • Abbr : CellMed
  • 2018, 8(3), pp.15-15
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine

Risa Parkordor Chen 1 Arun K. Yadav 1

1North-Eastern Hill University

Candidate

ABSTRACT

Helminthiasis is one of the most common worm diseases which causes a range of adverse health problems in humans. Ayurveda is one of the most prominent and ancient systems of traditional medicines in India. Most Ayurvedic drugs used against intestinal helminths have been developed by traditional wisdom and therefore lack a proper validation through controlled studies. The aim of the present study was to scientifically validate the in vitro efficacy of three common Indian Ayurvedic anthelmintic drugs, viz. Krimimudgar Ras, Kriminol and Vidangasava in relation to the synthetic broad-spectrum anthelmintic drugs, praziquantel and albendazole. The in vitro testing of Ayurvedic anthelmintics was done against an intestinal cestode, Raillietina sp. and a nematode, Syphacia obvelata, employing 10 mg/ml, 30 mg/ml and 50 mg/ml concentrations of each medicine. The anthelmintic efficacy was judged on the basis of paralysis and mortality time of worms after exposing to these Ayurvedic drugs. Of the three tested Ayurvedic medicines, Krimimudgar ras (KR) showed the most prominent efficacy, against both the cestode and nematode parasites. At 50 mg/ml concentration, KR caused mortality of cestodes in 7.53 ± 0.15 hr, and of nematodes in 7.61 ± 0.19 hr. Vidangasava was found to be comparatively less effective against the tested helminth parasites. The results of this study indicate that Ayurvedic formulations do possess significant anthelmintic effects, however, an evidence-based research is required to validate all currently used Ayurvedic anthelmintics, using proper controlled studies.

Citation status

* References for papers published after 2022 are currently being built.